Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.79USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$7.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
334,290
52-wk High
$15.01
52-wk Low
$4.10

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $571.14
Shares Outstanding(Mil.): 73.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

Nevada doctor indicted after patient overdoses on Insys-produced opioid

A Nevada doctor has been indicted on charges he regularly distributed a fentanyl-based cancer pain spray made by Insys Therapeutics Inc to someone who did not have a prescription and who subsequently overdosed on the powerful opioid.

Feb 14 2018

Maryland sues Insys to enforce subpoena in opioid probe

Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

Feb 08 2018

Maryland sues Insys to enforce subpoena in opioid probe

Feb 8 Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of an investigation into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

Feb 08 2018

New York accuses Insys of deceptively marketing opioid

Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.

Feb 01 2018

UPDATE 2-New York accuses Insys of deceptively marketing opioid

Feb 1 Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.

Feb 01 2018

New York accuses Insys of deceptively marketing opioid

Feb 1 New York's attorney general on Thursday filed a lawsuit against Insys Therapeutics Inc seeking $75 million from the pharmaceutical company, which he said deceptively promoted a powerful fentanyl-based cancer pain medicine for unsafe uses.

Feb 01 2018

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

Jan 11 2018

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

Jan 11 A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

Jan 11 2018

Ex-Insys employee in federal kickback case may face state charges

A former Insys Therapeutics Inc employee accused by federal prosecutors of engaging in a scheme to pay doctors kickbacks to prescribe a fentanyl-based spray may soon face additional charges by a state attorney general, according to court papers.

Jan 08 2018

Billionaire Insys founder switches lawyers, seeks trial delay

The billionaire founder of Insys Therapeutics Inc has shaken up his legal team and is seeking to delay trial over charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain medication.

Dec 27 2017

Earnings vs. Estimates